Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction.

Literature DB >> 18846042

Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction.

Abstract

The bradycardic agent ivabradine has proved to be of benefit in experimental models with the end points of ischaemic myocardial blood flow and contractile function, infarct size, post-infarct remodelling and atherosclerosis. The benefits to ischaemic myocardial blood flow and contractile function are strictly heart rate dependent; those on infarct size are partly heart rate independent. The heart rate dependency of ivabradine's benefit for atherosclerotic vascular function is contradictory, and that on post-infarct remodelling is entirely unclear.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2008 PMID： 18846042 PMCID： PMC2597255 DOI： 10.1038/bjp.2008.347

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

10 in total

1. Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations.

Authors: Guido Michels; Mathias C Brandt; Naufal Zagidullin; Ismail F Khan; Robert Larbig; Sebastian van Aaken; Jens Wippermann; Uta C Hoppe
Journal: Cardiovasc Res Date: 2008-02-05 Impact factor: 10.787

Review 2. alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans.

Authors: G Heusch; D Baumgart; P Camici; W Chilian; L Gregorini; O Hess; C Indolfi; O Rimoldi
Journal: Circulation Date: 2000-02-15 Impact factor: 29.690

3. Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol.

Authors: R Schulz; J Rose; A Skyschally; G Heusch
Journal: J Cardiovasc Pharmacol Date: 1995-02 Impact factor: 3.105

Review 4. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning.

Authors: Andreas Skyschally; Rainer Schulz; Gerd Heusch
Journal: Herz Date: 2008-03 Impact factor: 1.443

5. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction.

Authors: Gerd Heusch; Andreas Skyschally; Petra Gres; Patrick van Caster; Dustin Schilawa; Rainer Schulz
Journal: Eur Heart J Date: 2008-07-10 Impact factor: 29.983

6. Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis.

Authors: B D Guth; G Heusch; R Seitelberger; J Ross
Journal: Circulation Date: 1987-03 Impact factor: 29.690

7. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.

Authors: Florian Custodis; Magnus Baumhäkel; Nils Schlimmer; Franka List; Christoph Gensch; Michael Böhm; Ulrich Laufs
Journal: Circulation Date: 2008-04-28 Impact factor: 29.690

8. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice.

Authors: A Drouin; M-E Gendron; E Thorin; M-A Gillis; F Mahlberg-Gaudin; J-C Tardif
Journal: Br J Pharmacol Date: 2008-04-14 Impact factor: 8.739

Review 9. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.

Authors: G Heusch
Journal: Br J Pharmacol Date: 2008-01-28 Impact factor: 8.739

10. The properties of the pacemaker current I(F)in human ventricular myocytes are modulated by cardiac disease.

Authors: E Cerbai; L Sartiani; P DePaoli; R Pino; M Maccherini; F Bizzarri; F DiCiolla; G Davoli; G Sani; A Mugelli
Journal: J Mol Cell Cardiol Date: 2001-03 Impact factor: 5.000

10 in total

22 in total

Review 1. Antifungal proteins: targets, mechanisms and prospective applications.

Authors: T Theis; U Stahl
Journal: Cell Mol Life Sci Date: 2004-02 Impact factor: 9.261

2. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression.

Authors: S Suffredini; F Stillitano; L Comini; M Bouly; S Brogioni; C Ceconi; R Ferrari; A Mugelli; E Cerbai
Journal: Br J Pharmacol Date: 2012-03 Impact factor: 8.739

Review 3. Vascular endothelial ageing, heartbeat after heartbeat.

Authors: Eric Thorin; Nathalie Thorin-Trescases
Journal: Cardiovasc Res Date: 2009-07-07 Impact factor: 10.787

4. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression.

Authors: Nicolas Couvreur; Renaud Tissier; Sandrine Pons; Valérie Chetboul; Vassiliky Gouni; Patrick Bruneval; Chantal Mandet; Jean-Louis Pouchelon; Alain Berdeaux; Bijan Ghaleh
Journal: Eur Heart J Date: 2009-12-21 Impact factor: 29.983

10. Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis.

Authors: Li Yue-Chun; Zhang Teng; Zhou Na-Dan; Ge Li-Sha; Luo Qin; Guan Xue-Qiang; Lin Jia-Feng
Journal: PLoS One Date: 2012-06-28 Impact factor: 3.240